Commercial Supply Ambrisentan (CAS: 177036-94-1) Related Intermediates:
Ambrisentan CAS: 177036-94-1
Methyl 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoate CAS: 178306-47-3
2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid CAS: 178306-51-9
(S)-2-Hydroxy-3-Methoxy-3,3-Diphenylpropionic Acid CAS: 178306-52-0
L-Proline Methyl Ester Hydrochlorid CAS: 2133-40-6
4,6-Dimethyl-2-(Methylsulfonyl)pyrimidine CAS: 35144-22-0
| Chemical Name |
Ambrisentan |
| Synonyms |
(S)-2-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-Methoxy-3,3-Diphenylpropionic Acid; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-Methoxy-3,3-Diphenylpropanoic Acid |
| CAS Number |
177036-94-1 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C22H22N2O4 |
| Molecular Weight |
378.43 |
| Specific Rotation [α]D20 |
+170.0° to +176.0° (C=0.5, MeOH) |
| Melting Point |
172.0~178.0℃(dec.) |
| Solubility |
Very Soluble in Methanol; Soluble in Ethanol, Acetone; Insoluble in Water |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White or Off-White Powder |
| Identification |
HPLC; NMR; LC-MS |
| Related Substances |
|
| Individual Impurity |
≤0.50% |
| Total Impurities |
<1.00% |
| Loss on Drying |
≤0.50% |
| Residue on Ignition |
≤0.20% |
| Heavy Metals |
≤20ppm |
| Purity / Analysis Method |
>99.0% (HPLC) |
| Test Standard |
Enterprise Standard |
| Usage |
Pharmaceutical Intermediates |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
Ambrisentan (CAS: 177036-94-1) is a selective endothelin-A (ETA) receptor antagonist introduced for the oral treatment of patients with pulmonary arterial hypertension (PAH), to improve exercise capacity and delay clinical worsening. PAH is a rare disease of the small pulmonary arteries characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, and ultimately, right ventricular failure and premature death. Early symptoms of PAH include gradual onset of shortness of breath, fatigue, palpitation, edema, and fainting. Endothelin-1 (ET-1), a potent vasoconstrictor and smooth muscle mitogen, is a key contributor to the acceleration of the disease, and its effects are mediated through activation ofETA and ETB receptors. In June of 2007, the FDA granted approvalof ambrisentan for once-daily treatment of PAH.